pimavanserin — United Healthcare
hallucinations and delusions associated with Parkinson’s disease psychosis
Initial criteria
- Diagnosis of Parkinson’s disease
Reauthorization criteria
- Documentation of positive clinical response to Nuplazid therapy
Approval duration
12 months